Results 191 to 200 of about 8,834,434 (252)

Individuals 45 Years and Older in Opioid Agonist Treatment: A Scoping Review. [PDF]

Int J Environ Res Public Health
Gaulen Z, Lunde LH, Alpers SE, Carlsen SL.   +3 more
europepmc   +1 more source

Systematic profiling reveals broad G protein coupling and context‐dependent modulation of cyclic AMP by the orphan receptor GPR139

British Journal of Pharmacology, Volume 183, Issue 23, Page 6865-6882, December 2026.
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov, Hans Bräuner, Alexander Sebastian Hauser   +2 more
wiley   +1 more source

Disparities in Opioid Agonist Treatment Accessibility for Priority Populations in New South Wales, Australia. [PDF]

Drug Alcohol Rev
Conigrave JH, Dobbins T, Buckley NA, Lee KSK, Morley KC, Doyle M, Al-Ansari B, Wilson S, Loggins S, Conigrave K.   +9 more
europepmc   +1 more source

Signal detection and characterisation of a novel drug–drug interaction between methadone and a synthetic cannabinoid receptor agonist

British Journal of Pharmacology, Volume 183, Issue 23, Page 6787-6800, December 2026.
Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock, Louise M. Hesketh, Hongwei Cheng, Shuoqi Chen, Simon Hudson, Graeme Henderson, Jules C. Hancox, Michael J. Shattock, Michael J. Curtis, Caroline S. Copeland   +9 more
wiley   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all-cause mortality among people with opioid use disorder: A retrospective population-based target trial emulation study in British Columbia, Canada, 2010-2020. [PDF]

Addiction
Yan R, Min JE, Kurz M, Seaman SR, Bach P, Greenland S, Gustafson P, Karim ME, McCandless L, Platt RW, Siebert U, Socías ME, Xie H, Nosyk B.   +13 more
europepmc   +1 more source

Quality of life whilst ageing in opioid agonist treatment: a narrative analysis. [PDF]

BMC Public Health
Todd-Kvam J, Sugahara G, Muller AE, Clausen T.   +3 more
europepmc   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11143-11177, December 2026.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan   +4 more
wiley   +1 more source

"Anybody who Looks at This Program and Doesn't See the Positive Side from it Doesn't Fully Understand": Participant Perspectives on an Injectable Opioid Agonist Treatment Program in New Brunswick, Canada. [PDF]

Contemp Drug Probl
Thornton AN, Brunelle C, Scherf J.
europepmc   +1 more source